Statin modulation of human T-cell proliferation, IL-1 β and IL-17 production, and IFN- γ T cell expression: Synergy with conventional immunosuppressive agents

International Journal of Inflammation

Volumn 2013, Issue , 2013, Pages

  Jameel, Ashmal ^a   Ooi, Kenneth G J ^a   Jeffs, Natasha R ^a   Galatowicz, Grazyna ^a   Lightman, Susan L ^b   Calder, Virginia L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CD3 ANTIBODY; CYCLOSPORIN A; DEXAMETHASONE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SIMVASTATIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CELL VIABILITY; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84885622778     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2013/434586     Document Type: Article

References (50)

1. Blanco-Colio L. M., Tuñón J., Martín-Ventura J. L., Egido J., Anti-inflammatory and immunomodulatory effects of statins. Kidney International 2003 63 1 12 23 2-s2.0-0037213039 10.1046/j.1523-1755.2003.00744.x (Pubitemid 35463903)
2. Weitz-Schmidt G., Statins as anti-inflammatory agents. Trends in Pharmacological Sciences 2002 23 10 482 486 2-s2.0-0036805674 10.1016/S0165-6147(02)02077-1 (Pubitemid 35279610)
3. Niwa S., Totsuka T., Hayashi S., Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. International Journal of Immunopharmacology 1996 18 11 669 675 2-s2.0-0030292168 10.1016/S0192-0561(96)00068-9 (Pubitemid 27117938)
4. Lewis T. V., Dart A. M., Chin-Dusting J. P. F., Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. Journal of the American College of Cardiology 1999 33 3 805 812 2-s2.0-0033101497 10.1016/S0735-1097(98)00667-6
5. Greenwood J., Steinman L., Zamvil S. S., Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nature Reviews Immunology 2006 6 5 358 370 2-s2.0-33646354412 10.1038/nri1839
6. Nie C., Yang D., Liu G., Dong D., Ma Z., Fu H., Zhao Z., Sun Z., Statins induce immunosuppressive effect on heterotopic limb allografts in rat through inhibiting T cell activation and proliferation. European Journal of Pharmacology 2009 602 1 168 175 2-s2.0-57249109878 10.1016/j.ejphar.2008.11.022
7. Pahl H. L., Activators and target genes of Rel/NF- B transcription factors. Oncogene 1999 18 49 6853 6866 2-s2.0-0033596121
8. + lymphocytes. Journal of Immunology 2008 180 10 6988 6996 2-s2.0-45549102525
9. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., Singh I., Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004 363 9421 1607 1608 2-s2.0-2442561768 10.1016/S0140-6736(04)16205-3 (Pubitemid 38625664)
10. Sena A., Pedrosa R., Morais M. G., Therapeutic potential of lovastatin in multiple sclerosis. Journal of Neurology 2003 250 6 754 755 2-s2.0-0038458863 10.1007/s00415-003-1070-8 (Pubitemid 36718367)
11. Youssef S., Stüve O., Patarroyo J. O., Ruiz P. J., Radosevich J. L., Mi Hur E., Bravo M., Mitchell D. J., Sobel R. A., Stelnman L., Zamvil S. S., The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 420 6911 78 84 2-s2.0-0037038402 10.1038/nature01158 (Pubitemid 35291443)
12. Thomas P. B., Albini T., Giri R. K., See R. F., Evans M., Rao N. A., The effects of atorvastatin in experimental autoimmune uveitis. British Journal of Ophthalmology 2005 89 3 275 279 2-s2.0-14744271191 10.1136/bjo.2004.050401 (Pubitemid 40327606)
13. Gegg M. E., Harry R., Hankey D., Zambarakji H., Pryce G., Baker D., Adamson P., Calder V., Greenwood J., Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. Journal of Immunology 2005 174 4 2327 2335 2-s2.0-13544255743 (Pubitemid 40223982)
14. Kohno H., Sakai T., Saito S., Okano K., Kitahara K., Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Experimental Eye Research 2007 84 3 569 576 2-s2.0-33846799366 10.1016/j.exer.2006.11.011 (Pubitemid 46204698)
15. Leung B. P., Sattar N., Crilly A., Prach M., McCarey D. W., Payne H., Madhok R., Campbell C., Gracie J. A., Liew F. Y., McInnes I. B., A novel anti-inflammatory role for simvastatin in inflammatory arthritis. Journal of Immunology 2003 170 3 1524 1530 2-s2.0-0037309378 (Pubitemid 36139524)
16. Aprahamian T., Bonegio R., Rizzo J., Perlman H., Lefer D. J., Rifkin I. R., Walsh K., Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. Journal of Immunology 2006 177 5 3028 3034 2-s2.0-33747761951 (Pubitemid 44277819)
17. Koshy M., Berger D., Crow M. K., Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. Journal of Clinical Investigation 1996 98 3 826 837 2-s2.0-0029862164 (Pubitemid 26349188)
18. Pasceri V., Yeh E. T. H., A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999 100 21 2124 2126 2-s2.0-0033598672
19. Abou-Raya A., Abou-Raya S., Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmunity Reviews 2006 5 5 331 337 2-s2.0-33746934641 10.1016/j.autrev.2005.12.006 (Pubitemid 44202201)
20. Hill T., Galatowicz G., Akerele T., Lau C. H., Calder V., Lightman S., Intracellular T lymphocyte cytokine profiles in the aqueous humour of patients with uveitis and correlation with clinical phenotype. Clinical and Experimental Immunology 2005 139 1 132 137 2-s2.0-11244320571 10.1111/j.1365-2249.2005.02669. x (Pubitemid 40066138)
21. Weber C., Erl W., Weber K. S. C., Weber P. C., HMG-CoA reductase inhibitors decrease CD11b expression and CD11b- dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. Journal of the American College of Cardiology 1997 30 5 1212 1219 2-s2.0-0030838319 10.1016/S0735-1097(97)00324-0 (Pubitemid 27501437)
22. Kwak B., Mulhaupt F., Myit S., Mach F., Statins as a newly recognized type of immunomodulator. Nature Medicine 2000 6 12 1399 1402 2-s2.0-0034533147 10.1038/82219 (Pubitemid 32001026)
23. Jury E. C., Ehrenstein M. R., Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005 14 3 192 196 2-s2.0-15944384675 10.1191/0961203303lu2135oa (Pubitemid 40445582)
24. Wang J., Xiao Y., Luo M., Zhang X., Luo H., Statins for multiple sclerosis. Cochrane Database of Systematic Reviews 2010 12 CD008386 2-s2.0-79952200134
25. Bu D.-X., Tarrio M., Grabie N., Zhang Y., Yamazaki H., Stavrakis G., Maganto-Garcia E., Pepper-Cunningham Z., Jarolim P., Aikawa M., García-Cardeña G., Lichtman A. H., Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. Journal of Clinical Investigation 2010 120 6 1961 1970 2-s2.0-77953185420 10.1172/JCI41384
26. Bergman M., Salman H., Djaldetti M., Bessler H., Statins as modulators of colon cancer cells induced cytokine secretion by human PBMC. Vascular Pharmacology 2011 54 3-6 88 92 2-s2.0-79957958070 10.1016/j.vph.2011.03.002
27. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U., Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine 2001 7 6 687 692 2-s2.0-0034948339 10.1038/89058 (Pubitemid 32588024)
28. Björkhem-Bergman L., Lindh J. D., Bergman P., What is a relevant statin concentration in cell experiments claiming pleiotropic effects? British Journal of Clinical Pharmacology 2011 72 1 164 165 2-s2.0-79958723474 10.1111/j.1365-2125.2011.03907.x
29. Härtel C., Hammers H.-J., Schlenke P., Fricke L., Schumacher N., Kirchner H., Müller-Steinhardt M., Individual variability in cyclosporin A sensitivity: the assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes. Journal of Interferon and Cytokine Research 2003 23 2 91 99 2-s2.0-0345382796 10.1089/107999003321455480 (Pubitemid 36356879)
30. Franchimont D., Louis E., Dewe W., Martens H., Vrindts-Gevaert Y., De Groote D., Belaiche J., Geenen V., Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures. Regulatory Peptides 1998 73 1 59 65 2-s2.0-17944384067 10.1016/S0167-0115(97)01063-X (Pubitemid 28081895)
31. + subsets. Journal of Immunology 1995 155 7 3322 3328 2-s2.0-0029165831
32. Moed H., Stoof T. J., Boorsma D. M., Von Blomberg B. M. E., Gibbs S., Bruynzeel D. P., Scheper R. J., Rustemeyer T., Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles. Clinical and Experimental Allergy 2004 34 12 1868 1875 2-s2.0-11144325701 10.1111/j.1365-2222.2004.02124.x (Pubitemid 40023637)
33. Sehgal S. N., Sirolimus: its discovery, biological properties, and mechanism of action. Transplantation Proceedings 2003 35 3 S7 S14 2-s2.0-0038299000 10.1016/S0041-1345(03)00211-2 (Pubitemid 36547910)
34. Huang W.-Y., Cai Z., Sun W.-J., Lu G.-H., The effects of mycophenolic acid on the maturation and immunologic function of murine bone marrow-derived dendritic cells. Journal of Experimental Hematology 2004 12 2 207 212 2-s2.0-4444307003
35. Abadja F., Atemkeng S., Alamartine E., Berthoux F., Mariat C., Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation 2011 92 4 396 403 2-s2.0-80051724276 10.1097/TP.0b013e3182247b5f
36. Aktas O., Waiczies S., Smorodchenko A., Dörr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F., Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. Journal of Experimental Medicine 2003 197 6 725 733 2-s2.0-0037451121 10.1084/jem.20021425 (Pubitemid 36350867)
37. Li C. H., Li X. W., Li H., Duan L., Effects of lovastatin combined with cyclosporine A on cultured human peripheral blood mononuclear cells proliferation, cytokines expression and cytotoxicity. Acta Academiae Medicinae Sinicae 2001 23 6 614 618 2-s2.0-4344688055
38. Ascer E., Bertolami M. C., Venturinelli M. L., Buccheri V., Souza J., Nicolau J. C., Ramires J. A. F., Serrano C. V. Jr., Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004 177 1 161 166 2-s2.0-5444260617 10.1016/j.atherosclerosis.2004.07.003 (Pubitemid 39361151)
39. Kwak B., Mulhaupt F., Veillard N., Pelli G., Mach F., The HMG-CoA reductase inhibitor simvastatin inhibits IFN- γ induced MHC class II expression in human vascular endothelial cells. Swiss Medical Weekly 2001 131 3-4 41 46 2-s2.0-0035102526 (Pubitemid 32229957)
40. Chello M., Patti G., Candura D., Mastrobuoni S., Di Sciascio G., Agrò F., Carassiti M., Covino E., Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Critical Care Medicine 2006 34 3 660 667 2-s2.0-33644595198 10.1097/01.CCM.0000201407.89977.EA
41. Zineh I., Luo X., Welder G. J., DeBella A. E., Wessel T. R., Arant C. B., Schofield R. S., Chegini N., Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 2006 26 3 333 340 2-s2.0-33644680589 (Pubitemid 43334672)
42. Jury E. C., Isenberg D. A., Mauri C., Ehrenstein M. R., Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. Journal of Immunology 2006 177 10 7416 7422 2-s2.0-33750811623 (Pubitemid 44715112)
43. Aktunc E., Kayhan B., Arasli M., Gun B. D., Barut F., The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacology and Immunotoxicology 2011 33 4 667 675 2-s2.0-80755143841 10.3109/08923973.2011.559475
44. Stanislaus R., Gilg A. G., Singh A. K., Singh I., Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neuroscience Letters 2002 333 3 167 170 2-s2.0-0037195587 10.1016/S0304-3940(02) 00943-6 (Pubitemid 35335769)
45. Nath N., Giri S., Prasad R., Singh A. K., Singh I., Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. Journal of Immunology 2004 172 2 1273 1286 2-s2.0-1642454666 (Pubitemid 38113791)
46. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., Szczeklik A., Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. International Journal of Cardiology 2001 77 2-3 247 253 2-s2.0-0035138445 10.1016/S0167-5273(00)00439-3 (Pubitemid 32155911)
47. Wiklund O., Mattsson-Hultén L., Hurt-Camejo E., Oscarsson J., Effects of simvastatin and atorvastatin on inflammation markers in plasma. Journal of Internal Medicine 2002 251 4 338 347 2-s2.0-0036268290 10.1046/j.1365-2796.2002.00966.x (Pubitemid 34592108)
48. Erikstrup C., Ullum H., Pedersen B. K., Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation. Clinical and Experimental Immunology 2006 144 1 94 100 2-s2.0-33645104046 10.1111/j.1365-2249.2006.03042.x
49. Wæhre T., Damås J. K., Gullestad L., Holm A. M., Pedersen T. R., Arnesen K. E., Torsvik H., Frøland S. S., Semb A. G., Aukrust P., Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Journal of the American College of Cardiology 2003 41 9 1460 1467 2-s2.0-0038747064 10.1016/S0735-1097(03)00263-8 (Pubitemid 36543360)
50. Mondo C. K., Yang W.-S., Su J.-Z., Huang T.-G., Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat. Clinical and Experimental Hypertension 2006 28 5 499 509 2-s2.0-33745861349 10.1080/10641960600798713 (Pubitemid 44034674)